Broadly neutralizing antibodies target a haemagglutinin anchor epitope.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guthmiller Jenna J, Han Julianna, Utset Henry A, Li Lei, Lan Linda Yu-Ling, Henry Carole, Stamper Christopher T, McMahon Meagan, O'Dell George, Fernández-Quintero Monica L, Freyn Alec W, Amanat Fatima, Stovicek Olivia, Gentles Lauren, Richey Sara T, de la Peña Alba Torrents, Rosado Victoria, Dugan Haley L, Zheng Nai-Ying, Tepora Micah E, Bitar Dalia J, Changrob Siriruk, Strohmeier Shirin, Huang Min, García-Sastre Adolfo, Liedl Klaus R, Bloom Jesse D, Nachbagauer Raffael, Palese Peter, Krammer Florian, Coughlan Lynda, Ward Andrew B, Wilson Patrick C
Аннотация
Broadly neutralizing antibodies that target epitopes of haemagglutinin on the influenza virus have the potential to provide near universal protection against influenza virus infection1. However, viral mutants that escape broadly neutralizing antibodies have been reported2,3. The identification of broadly neutralizing antibody classes that can neutralize viral escape mutants is critical for universal influenza virus vaccine design. Here we report a distinct class of broadly neutralizing antibodies that target a discrete membrane-proximal anchor epitope of the haemagglutinin stalk domain. Anchor epitope-targeting antibodies are broadly neutralizing across H1 viruses and can cross-react with H2 and H5 viruses that are a pandemic threat. Antibodies that target this anchor epitope utilize a highly restricted repertoire, which encodes two public binding motifs that make extensive contacts with conserved residues in the fusion peptide. Moreover, anchor epitope-targeting B cells are common in the human memory B cell repertoire and were recalled in humans by an oil-in-water adjuvanted chimeric haemagglutinin vaccine4,5, which is a potential universal influenza virus vaccine. To maximize protection against seasonal and pandemic influenza viruses, vaccines should aim to boost this previously untapped source of broadly neutralizing antibodies that are widespread in the human memory B cell pool.